Lazard Asset Management
CAI

Lazard Asset Management’s Caris Life Sciences CAI Stock Holding History

Lazard Asset Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
81,736
-224,175
-73% -$4.01M ﹤0.01% 1106
2026
Q1 		$5.47M Buy
305,911
+63,132
+26% +$1.38M 0.01% 542
2025
Q4 		$6.55M Sell
242,779
-34,758
-13% -$979K 0.01% 495
2025
Q3 		$8.4M Buy
277,537
+107,608
+63% +$3.43M 0.01% 460
2025
Q2 		$4.54M Buy
+169,929
New +$4.58M 0.01% 757

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Lazard Asset Management's CAI Position: Q2 2026 in Review

Lazard Asset Management reduced its Caris Life Sciences (CAI) stake by 73% in Q2 2026, selling an estimated $4.01M and leaving 81,736 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1106.

Lazard Asset Management first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.4M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Lazard Asset Management held 81,736 shares of Caris Life Sciences worth $1.46M as of Q2 2026.
  • Lazard Asset Management sold 224,175 Caris Life Sciences shares in Q2 2026, an estimated $4.01M.
  • Caris Life Sciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1106 holding.
  • Lazard Asset Management first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Lazard Asset Management's Caris Life Sciences position peaked at $8.4M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.